ES2127819T3 - TREATMENT OF MACULAR DEGENERATION. - Google Patents

TREATMENT OF MACULAR DEGENERATION.

Info

Publication number
ES2127819T3
ES2127819T3 ES93909617T ES93909617T ES2127819T3 ES 2127819 T3 ES2127819 T3 ES 2127819T3 ES 93909617 T ES93909617 T ES 93909617T ES 93909617 T ES93909617 T ES 93909617T ES 2127819 T3 ES2127819 T3 ES 2127819T3
Authority
ES
Spain
Prior art keywords
macular degeneration
treatment
disease
deprenyl
ameliorate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909617T
Other languages
Spanish (es)
Inventor
Hastings Barbara A Fries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somerset Pharmaceuticals Inc
Original Assignee
Somerset Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals Inc filed Critical Somerset Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2127819T3 publication Critical patent/ES2127819T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Semiconductor Lasers (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating macular degeneration is disclosed which comprises administering to a patient suffering from the disease a therapeutically effective amount of L-deprenyl or a pharmaceutically acceptable acid addition salt thereof for a period of time sufficient to ameliorate the disease.
ES93909617T 1992-04-23 1993-04-23 TREATMENT OF MACULAR DEGENERATION. Expired - Lifetime ES2127819T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/872,839 US5242950A (en) 1992-04-23 1992-04-23 Treatment of macular degeneration

Publications (1)

Publication Number Publication Date
ES2127819T3 true ES2127819T3 (en) 1999-05-01

Family

ID=25360402

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909617T Expired - Lifetime ES2127819T3 (en) 1992-04-23 1993-04-23 TREATMENT OF MACULAR DEGENERATION.

Country Status (14)

Country Link
US (1) US5242950A (en)
EP (1) EP0637238B1 (en)
JP (1) JP2669721B2 (en)
AT (1) ATE175348T1 (en)
AU (1) AU679679B2 (en)
BR (1) BR9306283A (en)
CA (1) CA2133998C (en)
DE (1) DE69322957T2 (en)
DK (1) DK0637238T3 (en)
ES (1) ES2127819T3 (en)
GR (1) GR3029670T3 (en)
HU (1) HU224917B1 (en)
NO (1) NO944018L (en)
WO (1) WO1993021894A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US5783606A (en) * 1995-02-10 1998-07-21 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
AU723047B2 (en) * 1995-02-10 2000-08-17 University Of Toronto Innovations Foundation, The Deprenyl compounds for treatment of glaucoma
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
WO1996040085A2 (en) * 1995-06-07 1996-12-19 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5827652A (en) 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
ATE219358T1 (en) * 1995-11-06 2002-07-15 Somerset Pharmaceuticals Inc SUBLINGUAL AND BUCCAL ADMINISTRATION OF SELEGILINE
ATE222101T1 (en) 1998-03-16 2002-08-15 Somerset Pharmaceuticals Inc USE OF SELEGILINE OR DESMETHYLSELEGILINE TO TREAT WOUNDS, BURNS, AND SKIN DAMAGE
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
PT1441708E (en) * 2001-11-05 2009-06-18 Krele Pharmaceuticals Llc Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20040180090A1 (en) * 2003-03-12 2004-09-16 Demarco Peter Treatment of macular degeneration
JP2006524708A (en) * 2003-04-25 2006-11-02 インディヴァス ファーマシューティカルズ，インコーポレーテッド Method for promoting continuous sleep by administration of trospium chloride
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
JP2007512319A (en) * 2003-11-25 2007-05-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Compositions and methods for treating cardiovascular disorders and diseases
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (en) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd Use of propargylamine as neuroprotective agent
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
US20090208556A1 (en) * 2004-10-29 2009-08-20 Regents Of The University Of California, The Porous photonic crystals for drug delivery to the eye
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
KR20090034365A (en) * 2006-07-28 2009-04-07 알콘 리서치, 리미티드 Monoamine oxidase inhibitors useful for treating disorders of the outer retina
CN101815504B (en) 2007-07-10 2013-11-20 加利福尼亚大学董事会 Materials and methods for delivering compositions to selected tissues
RS58988B1 (en) 2010-02-03 2019-08-30 Pharma Two B Ltd Extended release formulations of rasagiline and uses thereof
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
CN107920964B (en) 2015-07-09 2022-02-25 加利福尼亚大学董事会 Fusogenic liposome-coated porous silicon nanoparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
CA2133998C (en) 2006-03-21
US5242950A (en) 1993-09-07
DE69322957D1 (en) 1999-02-18
HU9403052D0 (en) 1994-12-28
NO944018D0 (en) 1994-10-21
HUT72295A (en) 1996-04-29
AU679679B2 (en) 1997-07-10
JPH07505906A (en) 1995-06-29
DK0637238T3 (en) 1999-08-30
WO1993021894A3 (en) 1994-01-20
ATE175348T1 (en) 1999-01-15
JP2669721B2 (en) 1997-10-29
HU224917B1 (en) 2006-04-28
NO944018L (en) 1994-10-21
GR3029670T3 (en) 1999-06-30
EP0637238A1 (en) 1995-02-08
BR9306283A (en) 1998-06-30
EP0637238B1 (en) 1999-01-07
DE69322957T2 (en) 1999-07-01
AU4033993A (en) 1993-11-29
CA2133998A1 (en) 1993-11-11
WO1993021894A2 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
ES2127819T3 (en) TREATMENT OF MACULAR DEGENERATION.
PT668763E (en) USE OF FENSERIN FOR THE PREPARATION OF MEDICINES TO TREAT DISEASES OF KNOWLEDGE
ES2166381T3 (en) TREATMENT OF HYPERPROLIFERATIVE VASCULAR DISEASES.
DK0796103T3 (en) Use of incense to treat Alzheimer's disease
DK0501705T3 (en) Use of tomoxetine for the treatment of diseases of the lower urinary tract
DE4394931T1 (en) Use of norastemizole for the treatment of allergic diseases
MY104521A (en) Treatment of depression.
DE69307702D1 (en) USE OF (E) - 2 - (P -FLUOROPHENETHYL) - 3 - FLUOROALLYLAMINE FOR TREATING ALZHEIMER'S DISEASE
ES2117008T3 (en) METHOD OF TREATMENT WITH AMPEROZIDE OF SCHIZOPHRENIA RESISTANT TO THERAPY.
EA200200559A1 (en) METHOD OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE CONDITIONS
NO984196L (en) Procedure for the treatment of substance abuse
DE69800906D1 (en) Use of olanzapine in the manufacture of a medicament for the treatment of cerebral focal ischemia
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
NO961180L (en) Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease
RU93046326A (en) METHOD OF TREATMENT OF MEDICAMENTAL EZOPHAGO-GINGOVO-STOMATITIS
RU1821745C (en) Method for prognosticating effectiveness of efferent therapeutic treatment of patients suffering from immunocomplex diseases
IL90059A0 (en) Paromomycin or its derivatives or salts thereof for treatment of human parasitic diseases
ATE316373T1 (en) CONAGENIN FOR THE TREATMENT OF ULCERATIVE COLITIS AND/OR CROHN'S DISEASE
MX9704887A (en) Pharmaceutical compositions for the treatment of depressive disorders.
DK8893D0 (en) MEDICAMENT FOR TREATMENT OR PREVENTION OF DISEASE

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 637238

Country of ref document: ES